T1	Participants 32 103	children with systemic ventricular dysfunction treated with carvedilol.
T2	Participants 199 219	adults and children.
T3	Participants 502 633	in a population of children with systemic ventricular dysfunction and symptomatic heart failure treated with carvedilol or placebo.
T4	Participants 690 772	Pediatric Carvedilol Trial (PCT) participants (carvedilol n = 161; placebo n = 55)
T5	Participants 1098 1130	children treated with carvedilol
T6	Participants 1354 1371	carvedilol group.
T7	Participants 1418 1426	children
